Semaglutide linked to 26% lower 5-year predicted dementia risk
Summary
A study finds that Semaglutide, a drug for diabetes and weight loss, is associated with a 26% lower predicted risk of dementia over a 5-year period.
Similar Articles
Weight-loss drugs show signs of slowing biological aging, say drugmakers
Novo Nordisk and Eli Lilly report that GLP-1 weight-loss drugs such as semaglutide reduce molecular aging-clock markers by roughly two to four years, suggesting these medications may act as geroprotectors that slow biological aging.
Hair Loss Was Just the Start. Ozempic Users Are Also Reporting Nail Trouble
European researchers found that GLP-1 users are significantly more likely to develop hair loss and nail problems, particularly nail detachment, compared to non-users, adding to known risks of semaglutide and tirzepatide.
Most powerful obesity drug yet: People lost up to 25% of weight in trial
A next-generation obesity drug, Retatrutide, shows up to 25% weight loss in clinical trials, building on GLP-1 based treatments by combining GLP-1, GIP, and glucagon hormones.
Popular weight loss drugs linked to a surprising fingernail problem
A multinational controlled study presented at the EADV Congress 2026 found that GLP-1 weight loss and diabetes drugs (Ozempic, Wegovy, Mounjaro, Zepbound) are associated with a significantly higher rate of nail detachment and discoloration, with weight loss alone not fully explaining the effect.
Routine vaccines may cut dementia risk—experts have startling hypothesis on how
Routine vaccines like those for flu, shingles, and Tdap are linked to lower dementia risk, with a new hypothesis suggesting they may train the innate immune system, previously thought untrainable, offering potential new avenues for dementia prevention.